Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study.
Gilad ShermanGabriella S LambTanvi S SharmaElizabeth C LloydJerod NagelNada N DandamCarlos R OliveiraHassan S SheikhaBrenda I AnosikePhilip LeeSurabhi B VoraKarisma PatelPaul K SueBeenish RubbabApril M YarbroughLakshmi GanapathiMari M NakamuraPublished in: Journal of the Pediatric Infectious Diseases Society (2023)
Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.